We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Interview: CDER OND Director Stein on Novel Drugs, Expedited Approval Pathways
Interview: CDER OND Director Stein on Novel Drugs, Expedited Approval Pathways
CDER’s Office of New Drugs (OND) Director Peter Stein is a nationally recognized leader in pharmaceutical research and development. Before joining the FDA in 2016 as OND deputy director he was a vice president at Merck Research Laboratories and formerly a vice president at Janssen.